Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emtricitabine/tenofovir alafenamide - Gilead Sciences

Drug Profile

Emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: DESCOVY; Descovy; F/TAF; Tenofovir alafenamide/emtricitabine

Latest Information Update: 31 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 06 Nov 2019 Updated efficacy and adverse events data from the phase III DISCOVER trial in HIV-1 infections released by Gilead Sciences
  • 06 Nov 2019 Gilead Sciences plans a clinical trial in HIV-1 infections (In adolescent women, In cisgender women) in Africa (PO)
  • 04 Oct 2019 Launched for HIV-1 infections (In adolescents, Prevention, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top